FOLH1 and neoplasm: Deberle and colleagues [22] evaluated 177Lu-Ibu-diaminobutyric acid (DAB)-PSMA in the preclinical setting and found that it was able to accumulate 40% higher in the tumor compared with 177Lu-PSMA-617 while being quickly cleared in the blood and kidneys in murine models.